Hepatitis Monthly

Published by: Kowsar

A Study of CC-Chemokine Receptor 5 (CCR5) Polymorphism on the Outcome of HCV Therapy in Egyptian Patients

Moataza H Omran 1 , * , Mahmoud Khamis 2 , Nada Nasr 2 , Ahmed A Massoud 3 , Samar S Youssef 1 , Noha G. Bader El Din 1 , Reham M Dawood 1 , Khaled Atef 1 , Rehab I Moustafa 1 , Wael Nabil 1 , Ashraf A Tabll 1 and Mostafa K. El Awady 1
Authors Information
1 Microbial Biotechnology Department, Genetic Engineering Division, National Research Centre, Cairo, Egypt
2 Zoology Department, Faculty of Dentistery, Modern Science and Arts University (MSA), Cairo, Egypt
3 Zoology Department, Faculty of Science, Tanta University, Cairo, Egypt
Article information
  • Hepatitis Monthly: December 01, 2013, 13 (12); e13721
  • Published Online: December 19, 2013
  • Article Type: Research Article
  • Received: July 20, 2013
  • Revised: September 7, 2013
  • Accepted: October 2, 2013
  • DOI: 10.5812/hepatmon.13721

To Cite: Omran M H, Khamis M, Nasr N, Massoud A A, Youssef S S, et al. A Study of CC-Chemokine Receptor 5 (CCR5) Polymorphism on the Outcome of HCV Therapy in Egyptian Patients, Hepat Mon. 2013 ;13(12):e13721. doi: 10.5812/hepatmon.13721.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg. 2002; 67(4): 436-42[PubMed]
  • 2. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005; 100(11): 2447-52[DOI][PubMed]
  • 3. Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2005; 165(19): 2206-12[DOI][PubMed]
  • 4. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician. 2005; 72(4): 655-62[PubMed]
  • 5. Rocha D, Gut I, Jeffreys AJ, Kwok PY, Brookes AJ, Chanock SJ. Seventh international meeting on single nucleotide polymorphism and complex genome analysis: 'ever bigger scans and an increasingly variable genome'. Hum Genet. 2006; 119(4): 451-6[DOI][PubMed]
  • 6. Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG, et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res. 2005; 25(5): 271-6[DOI][PubMed]
  • 7. Konishi I, Horiike N, Hiasa Y, Michitaka K, Onji M. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology. 2004; 47(2): 114-20[DOI][PubMed]
  • 8. Omran MH, Fotouh BE, Youssef SS, Ibrahim NE, Nabil W, Mahdy el SM, et al. Association between low molecular polypeptide 7 single nucleotide polymorphism and response to therapy in hepatitis C virus infection. World J Hepatol. 2013; 5(3): 97-103[DOI][PubMed]
  • 9. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354(6): 610-21[DOI][PubMed]
  • 10. Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol. 2000; 12(4): 403-8[PubMed]
  • 11. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997; 35(1): 201-7[PubMed]
  • 12. Armitage PG. Statistical methods in medical research. 2000;
  • 13. Riffenburgh RH. Statistics in Medicine. 2006;
  • 14. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000; 191(9): 1499-512[PubMed]
  • 15. Larrubia JR, Benito-Martinez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol. 2008; 14(47): 7149-59[PubMed]
  • 16. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357(2): 124-34[DOI][PubMed]
  • 17. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat. 2009; 16(10): 724-31[DOI][PubMed]
  • 18. Sugimoto Y, Kuzushita N, Takehara T, Kanto T, Tatsumi T, Miyagi T, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat. 2002; 9(5): 377-84[PubMed]
  • 19. Yuan Y, Shimizu I, Shen M, Aoyagi E, Takenaka H, Itagaki T, et al. Effects of estradiol and progesterone on the proinflammatory cytokine production by mononuclear cells from patients with chronic hepatitis C. World J Gastroenterol. 2008; 14(14): 2200-7[PubMed]
  • 20. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006; 130(4): 1086-97[DOI][PubMed]
  • 21. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9): 1259-69[DOI][PubMed]
  • 22. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-20[DOI][PubMed]
  • 23. Blanca OC. Predictive factors for response to treatment of Chronic Hepatitis. Ann hepatology. 2006; 5: 24-8
  • 24. Nadeem A, Hussain MM, Aslam M, Hussain T, Butt IF, Ali Khan S, et al. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy. J Ayub Med Coll Abbottabad. 2009; 21(2): 103-6[PubMed]
  • 25. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis. 2004; 24 Suppl 2: 25-31[DOI][PubMed]
  • 26. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C, et al. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther. 2007; 12(5): 797-803[PubMed]
  • 27. Ksiaa Cheikh Rouhou L, Gorgi YL, Skhiri HA, Aouadi H, Ayed SJ, Sfar I, et al. Chemokine and chemokine receptor gene polymorphism in Tunisian hemodialysis patients with HCV infection. Arab J Nephrol Transplant. 2011; 4(3): 117-24[PubMed]
  • 28. Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology. 2003; 124(2): 352-60[DOI][PubMed]
  • 29. Coenen M, Nattermann J. The role of CCR5 in HCV infection. Eur J Med Res. 2010; 15(3): 97-101[PubMed]
  • 30. Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol. 2000; 12(9): 1311-8[PubMed]
  • 31. Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what's going on? J Immunol. 2006; 177(4): 2039-45[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments